glp 1 agonist anti inflammatory The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury GLP-1 Agonist to Treat Obesity

ELIXA trial included patients with recent cardiovascular event (patients with acute coronary syndrome 180 days before randomization), and although there was no benefit in MACE reduction in lixisenatide treated patients compared to placebo, results revealed cardiovascular safety of lixisenatide in this specific high risk population (38, 40)

If your doctor needs guidance on how to qualify for semaglutide through insurance, this documentation checklist is the starting point

Notably, the SOS study showed that in people with T2D, achieving and maintaining 15% WL over 15 years was associated with reductions in both micro- and macrovascular complications following BS [54]

Novo Nordisk, the Danish pharma company behind several GLP-1RA drugs (including Ozempic/Wegovy and Saxenda) grew its sales by over 30% in 2023, and its share price rose by over 70% in the last year, making it the most valuable European company by market capitalization